Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Inivata is a Leader in Liquid Biopsy

Unlocking essential genomic information from a simple
blood draw to transform the care of cancer patients

Liquid Biopsy Unlocking essential genomic information from a simple blood draw to transform the care of cancer patients

InVision® platform

Our InVision® platform unlocks essential genomic information from a simple blood draw to transform the care of cancer patients

InVisionFirst®Lung Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

InVisionFirst®Lung

Our US Medicare-reimbursed lead product InVisionFirst®Lung is already transforming the lives of advanced NSCLC patients

Radar™  A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Radar

A multi-tumor assay for the detection of residual disease and recurrence based on the InVision® liquid biopsy platform

Our Mission

We are transforming the lives of cancer patients and their families through the power of liquid biopsy

InvisionFirst Lung - ctDNA Liquid Biopsy Test

Our Technology - Liquid Biopsy Testing

Our Technology

Contact Us at Inivata

Contact Us

Latest News and Events

Inivata to be Acquired by NeoGenomics

Exercise of purchase option to acquire remaining Inivata equity interest for $390m. Inivata to become a liquid biopsy focused division ... Read More

Molecular Residual Disease detection in early stage breast cancer with a personalized sequencing approach

Rosalind Cutts, Maria Coakley, Isaac Garcia-Murillas, Lara Ulrich, Karen Howarth, Warren Emmett, Malcolm Perry, Pete Ellis, Charlene ... Read More

AACR Annual Meeting Week 2

AACR Annual Meeting Week 2

Event expiration date display - 17 - 21 MAY 2021

Location: Online Event Read More

Changing Lives

Patients are at the heart of everything we do.

Our first product is for advanced Non-Small Cell lung Cancer and our world-leading tests are already impacting patients’ lives. 

This is the story of the first patient Inivata tested.

Transforming the lives of Cancer Patients and Their Families

As a dynamic and innovative company, we focus on the development of ground-breaking technology in a fast-paced and international setting.

Our team of talented and driven individuals work together to combine their energy and expertise in world-class research, product development and commercialization. Join us.

As part of the acquisition, Inivata will remain a separate business division alongside @NeoGenomics’ growing clinical, pharma and informatics divisions, with our CEO Clive Morris becoming President of Inivata. Read more here: https://bit.ly/3aZAfen

Our acquisition by @NeoGenomics follows a $25 million minority equity investment in #Inivata in May 2020, at which the Company was granted a fixed price option to purchase the remainder of #Inivata for $390 million. Learn more here: https://bit.ly/3aZAfen

Precision cancer diagnostics company @Inivata agrees to $390m acquisition by @NeoGenomics, offering exits to @IPGroupplc and @cic_vc https://globaluniversityventuring.com/inivata-inspires-390m-acquisition/